Testosterone Antagonizes Doxorubicin‐Induced Senescence of Cardiomyocytes
Open Access
- 13 January 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (1)
Abstract
Background: Chronic cardiotoxicity is less common in male than in female patients receiving doxorubicin and other anthracyclines at puberty and adolescence. We hypothesized that this sex difference might be secondary to distinct activities of sex hormones on cardiomyocyte senescence, which is thought to be central to the development of long‐term anthracycline cardiomyopathy. Methods and Results: H9c2 cells and neonatal mouse cardiomyocytes were exposed to doxorubicin with or without prior incubation with testosterone or 17β‐estradiol, the main androgen and estrogen, respectively. Testosterone, but not 17β‐estradiol, counteracted doxorubicin‐elicited senescence. Downregulation of telomere binding factor 2, which has been pinpointed previously as being pivotal to doxorubicin‐induced senescence, was also prevented by testosterone, as were p53 phosphorylation and accumulation. Pretreatment with the androgen receptor antagonist flutamide, the phosphatidylinositol 3 kinase inhibitor LY 294002, and the nitric oxide synthase inhibitor L‐ NG ‐nitroarginine methyl ester abrogated the reduction in senescence and the normalization of telomere binding factor 2 levels attained by testosterone. Consistently, testosterone enhanced the phosphorylation of AKT and nitric oxide synthase 3. In H9c2 cells, doxorubicin‐stimulated senescence was still observed up to 21 days after treatment and increased further when cells were rechallenged with doxorubicin 14 days after the first exposure to mimic the schedule of anthracycline‐containing chemotherapy. Remarkably, these effects were also inhibited by testosterone. Conclusions: Testosterone protects cardiomyocytes against senescence caused by doxorubicin at least in part by modulating telomere binding factor 2 via a pathway involving the androgen receptor, phosphatidylinositol 3 kinase, AKT , and nitric oxide synthase 3. This is a potential mechanism by which pubescent and adolescent boys are less prone to chronic anthracycline cardiotoxicity than girls.Keywords
This publication has 49 references indexed in Scilit:
- Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective TherapiesJournal of the American Heart Association, 2014
- Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac DysfunctionEuropean Journal of Heart Failure, 2014
- Doxorubicin induces senescence and impairs function of human cardiac progenitor cellsBasic Research in Cardiology, 2013
- Androgen Receptor Counteracts Doxorubicin-Induced Cardiotoxicity in Male MiceMolecular Endocrinology, 2010
- Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult MiceCirculation, 2010
- Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2American Journal of Physiology-Heart and Circulatory Physiology, 2009
- Cardiovascular Complications of Cancer TherapyJACC, 2009
- Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damageAging Cell, 2007
- Congestive Heart Failure After Treatment for Wilms’ Tumor: A Report From the National Wilms’ Tumor Study GroupJournal of Clinical Oncology, 2001
- Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood CancerNew England Journal of Medicine, 1995